Ertapenem plus meropenem combination treatment in carbapenem-resistant <i>Klebsiella pneumoniae</i> bacteremia: an analysis of 53 cases
Makaleler > Tam Makale · 2023
Yazarlar: Ugur Onal, Deniz Akyol, Arda Kaya, Dilsah Baskol, Buse Kenanoglu, Gamze Sanlidag, Ayse Uyan Onal, Cansu Bulut Avsar, Merve Mert, Seichan Memetali, Hüseyin Aytaç ERDEM, Devrim BOZKURT, Adnan Simsir, Osman BOZBIYIK, Ümit KAHRAMAN, Erkin Ozgiray, Pervin Korkmaz, Feriha Cilli, Husnu Pullukcu, Tansu Yamazhan, Meltem Isikgoz Tasbakan, Bilgin Arda, Sercan Ulusoy, Oğuz Reşat SİPAHİ
EUROPEAN JOURNAL OF CLINICAL MICROBIOLOGY & INFECTIOUS DISEASES, SCI İndekslerine Giren Dergi, Uluslararası, Wos, 2023, cilt 42, ss 1269-1273
DOI: 10.1007/s10096-023-04660-3
Özet
Herein, we aimed to describe the outcomes of patients with blood stream infections due to carbapenem-resistant Klebsiella pneumoniae (CR-Kp) who received ertapenem plus meropenem combination treatment (EMCT). A total of 53 patients with culture proven CR-Kp bacteremia treated with ertapenem + meropenem were included. The patients with secondary bacteremia due to urinary tract infection exhibited a significantly lower 1-month mortality (OMM), particularly in those with microbiological eradication and those with end-of-treatment success. Salvage EMCT resulted in 49% 1-month survival.